Oric Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 100
- Market Cap
- $704.7M
- Website
- http://www.oricpharma.com
- Introduction
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rules
ORIC Pharmaceuticals granted 16,400 stock options and 2,800 restricted stock units to a new employee under its 2022 Inducement Equity Incentive Plan. Vesting occurs over time, with specifics outlined. The grants aim to attract talent, approved by ORIC's Compensation Committee, aligning with Nasdaq rules. ORIC focuses on overcoming cancer resistance, developing treatments like ORIC-114 and ORIC-944.
Short Seller Sentiment is Bearish on This Cancer Stock
AI is the greatest investment opportunity, poised for exponential growth across industries. Early investors can reap massive rewards, akin to early internet investors. Disruption by AI is inevitable, with top talent driving innovation. A specific AI stock offers potential for a 10,000% return, and exclusive insights are available through a discounted newsletter subscription.
Michael Hostetler: Expert in IP Strategy for FDA-Approved Drugs and Clinical Trials
Expert in IP strategy for FDA-approved drugs and clinical trials, with significant M&A experience in pharma. Represented numerous companies and investors in financings, IPOs, and IP diligence. Co-creator of healthcare investment initiatives and board member at LaunchBio.
© Copyright 2025. All Rights Reserved by MedPath